<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic research plays an important role in the <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e> genotyping and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> clinical treatment recently </plain></SENT>
<SENT sid="1" pm="."><plain>Epigenetics is the study of changes in gene function that are mitotically and/or meiotically heritable and that do not entail a change in DNA sequence, including DNA methylation and <z:chebi fb="0" ids="15358">histone</z:chebi> modifications </plain></SENT>
<SENT sid="2" pm="."><plain>DNA methylation is one of the most important epigenetic modifications often occurring on the <z:chebi fb="1" ids="16040">cytosine</z:chebi> of CpG islands located in gene promoter regions, which is thought to be closely correlated with <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>The inducibility and reversibility of DNA methylation provide us an insight into <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development and treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Aberrant DNA hypermethylation is associated with the progress of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="5" pm="."><plain>The DNA methyltransferase inhibitors (azacytidine and <z:chebi fb="0" ids="50131">decitabine</z:chebi>) have achieved<z:chebi fb="9" ids="37952"> suc</z:chebi>-cess in treating high-and intermediate-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>This will bring new ideas to understand the cause and develop the treat-ment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>This review mainly introduces the latest progress of the action mechanism of those two medicines, the clini-cal effect and new problems during the clinical application on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>